RALLYBIO CORPORATION Research and Development Expense
RALLYBIO CORPORATION (RLYB) reported Research and Development Expense of $758.00 thousand for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-26
- RALLYBIO CORPORATION research and development expense for the quarter ending 2026-06-30 was $758.00K, a 87.52% decline year-over-year.
- RALLYBIO CORPORATION research and development expense for the quarter ending 2026-03-31 was $2.87M, a 49.85% decline year-over-year.
- RALLYBIO CORPORATION research and development expense for the quarter ending 2025-12-31 was $3.65M, a 50.51% decline year-over-year.
- RALLYBIO CORPORATION research and development expense for the quarter ending 2025-09-30 was $4.14M, a 49.72% decline year-over-year.
- RALLYBIO CORPORATION research and development expense for fiscal 2023 was $53.54M, a 31.59% increase from fiscal 2022.
- RALLYBIO CORPORATION research and development expense for fiscal 2022 was $40.69M, a 51.21% increase from fiscal 2021.
- RALLYBIO CORPORATION research and development expense for fiscal 2021 was $26.91M, a 52.63% increase from fiscal 2020.
- RALLYBIO CORPORATION research and development expense for fiscal 2020 was $17.63M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $758.00K S-4/A · filed 2026-08-26 | $3.63M S-4/A · filed 2026-08-26 | $7.28M derived: sum of 3 quarters · filed 2026-08-26 | $11.43M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $2.87M S-4 · filed 2026-07-15 | $6.53M derived: sum of 2 quarters · filed 2026-08-26 | $10.67M derived: sum of 3 quarters · filed 2026-08-26 | $16.74M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $3.65M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $7.80M derived: sum of 2 quarters · filed 2026-08-26 | $13.87M derived: sum of 3 quarters · filed 2026-08-26 | $19.60M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $4.14M 10-Q · filed 2025-11-06 | $10.22M derived: sum of 2 quarters · filed 2026-08-26 | $15.94M 10-Q · filed 2025-11-06 | $23.33M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $6.07M S-4/A · filed 2026-08-26 | $11.80M S-4/A · filed 2026-08-26 | $19.18M derived: sum of 3 quarters · filed 2026-08-26 | $27.42M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $5.72M S-4 · filed 2026-07-15 | $13.11M derived: sum of 2 quarters · filed 2026-08-26 | $21.35M derived: sum of 3 quarters · filed 2026-08-26 | $34.30M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | $7.38M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $15.63M derived: sum of 2 quarters · filed 2026-08-26 | $28.57M derived: sum of 3 quarters · filed 2026-08-26 | $41.51M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $8.24M 10-Q · filed 2025-11-06 | $21.19M derived: sum of 2 quarters · filed 2025-11-06 | $34.12M 10-Q · filed 2025-11-06 | $50.05M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.95M 10-Q · filed 2025-08-07 | $25.88M 10-Q · filed 2025-08-07 | $41.81M derived: sum of 3 quarters · filed 2025-08-07 | $55.09M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $12.94M 10-Q · filed 2025-05-08 | $28.86M derived: sum of 2 quarters · filed 2025-05-08 | $42.15M derived: sum of 3 quarters · filed 2025-05-08 | $55.28M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $15.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $29.21M derived: sum of 2 quarters · filed 2025-03-13 | $42.34M derived: sum of 3 quarters · filed 2025-03-13 | $53.54M 10-K · filed 2025-03-13 |
| 2023-09-30 | $13.29M 10-Q · filed 2024-11-07 | $26.42M derived: sum of 2 quarters · filed 2024-11-07 | $37.62M 10-Q · filed 2024-11-07 | $48.41M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $13.13M 10-Q · filed 2024-08-08 | $24.33M 10-Q · filed 2024-08-08 | $35.13M derived: sum of 3 quarters · filed 2024-08-08 | $47.23M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $11.20M 10-Q · filed 2024-05-09 | $22.00M derived: sum of 2 quarters · filed 2024-05-09 | $34.10M derived: sum of 3 quarters · filed 2024-05-09 | $44.24M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $22.90M derived: sum of 2 quarters · filed 2024-03-12 | $33.04M derived: sum of 3 quarters · filed 2024-03-12 | $40.69M 10-K · filed 2024-03-12 |
| 2022-09-30 | $12.11M 10-Q · filed 2023-11-09 | $22.25M derived: sum of 2 quarters · filed 2023-11-09 | $29.90M 10-Q · filed 2023-11-09 | $35.99M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $10.14M 10-Q · filed 2023-08-08 | $17.79M 10-Q · filed 2023-08-08 | $23.88M derived: sum of 3 quarters · filed 2023-08-08 | $28.84M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $7.65M 10-Q · filed 2023-05-09 | $13.74M derived: sum of 2 quarters · filed 2023-05-09 | $18.70M derived: sum of 3 quarters · filed 2023-05-09 | $25.52M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $11.05M derived: sum of 2 quarters · filed 2023-03-06 | $17.87M derived: sum of 3 quarters · filed 2023-03-06 | $26.91M 10-K · filed 2023-03-06 |
| 2021-09-30 | $4.96M 10-Q · filed 2022-11-07 | $11.78M derived: sum of 2 quarters · filed 2022-11-07 | $20.82M 10-Q · filed 2022-11-07 | $28.31M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $6.82M 10-Q · filed 2022-08-08 | $15.86M 10-Q · filed 2022-08-08 | $23.35M derived: sum of 3 quarters · filed 2022-08-08 | $28.48M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $9.04M 10-Q · filed 2022-05-10 | $16.53M derived: sum of 2 quarters · filed 2022-05-10 | $21.66M derived: sum of 3 quarters · filed 2022-05-10 | $24.75M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $12.63M derived: sum of 2 quarters · filed 2022-03-15 | $15.72M derived: sum of 3 quarters · filed 2022-03-15 | $17.63M 10-K · filed 2022-03-15 |
| 2020-09-30 | $5.13M 10-Q · filed 2021-11-10 | $8.22M derived: sum of 2 quarters · filed 2021-11-10 | $10.13M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.09M 10-Q · filed 2021-09-09 | $5.00M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |